Galena Biopharma Receives 2013 Global Frost & Sullivan Award for New Product Innovation for NeuVax&#0153

Published: Mar 14, 2013

LAKE OSWEGO, Ore., March 14, 2013 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE), a biopharmaceutical company developing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, announced that independent research firm, Frost & Sullivan, has recognized Galena Biopharma with the 2013 Global Frost & Sullivan Award for New Product Innovation. The Company accepted the honor at the Frost & Sullivan Award Gala, held March 12, 2013 in San Diego, CA.

Back to news